Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Athira Pharma stock

Own Athira Pharma stock in just a few minutes.

Updated . What changed?

Fact checked

Athira Pharma, Inc is a biotechnology business based in the US. Athira Pharma shares (ATHA) are listed on the NASDAQ and all prices are listed in US Dollars.

How to buy shares in Athira Pharma

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Athira Pharma. Find the stock by name or ticker symbol: ATHA. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Athira Pharma reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Athira Pharma, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Athira Pharma. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Athira Pharma share price

Use our graph to track the performance of ATHA stocks over time.

Athira Pharma shares at a glance

Information last updated 2021-02-23.
52-week rangeUSD$15.79 - USD$34.79
50-day moving average USD$23.7365
200-day moving average USD$23.0587
Wall St. target priceUSD$44.25
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Buy Athira Pharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Robinhood
$0
Stocks, Options, ETFs, Gold/Commodities
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Tastyworks
$0
Stocks, Options, Cryptocurrency
Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg
Futures: $2.50/contract to open, $0 to close
0%
Get 100 shares of stock (worth $1 to $6 a share)
Open and fund a new cash or margin account with $2,000+
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
N/A
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TradeStation
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Athira Pharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Athira Pharma financials

Gross profit TTM USD$0
Return on assets TTM 0%
Return on equity TTM 0%
Profit margin 0%
Book value N/A
Market capitalisation USD$812.2 million

TTM: trailing 12 months

Shorting Athira Pharma shares

There are currently 807,897 Athira Pharma shares held short by investors – that's known as Athira Pharma's "short interest". This figure is 13.8% down from 937,207 last month.

There are a few different ways that this level of interest in shorting Athira Pharma shares can be evaluated.

Athira Pharma's "short interest ratio" (SIR)

Athira Pharma's "short interest ratio" (SIR) is the quantity of Athira Pharma shares currently shorted divided by the average quantity of Athira Pharma shares traded daily (recently around 453874.71910112). Athira Pharma's SIR currently stands at 1.78. In other words for every 100,000 Athira Pharma shares traded daily on the market, roughly 1780 shares are currently held short.

To gain some more context, you can compare Athira Pharma's short interest ratio against those of similar companies.

However Athira Pharma's short interest can also be evaluated against the total number of Athira Pharma shares, or, against the total number of tradable Athira Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Athira Pharma's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Athira Pharma shares in existence, roughly 20 shares are currently held short) or 0.0247% of the tradable shares (for every 100,000 tradable Athira Pharma shares, roughly 25 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Athira Pharma.

Find out more about how you can short Athira Pharma stock.

Athira Pharma share dividends

We're not expecting Athira Pharma to pay a dividend over the next 12 months.

Athira Pharma overview

Athira Pharma, Inc., a clinical-stage biopharmaceutical company, develops small molecules to restore neuronal health and stop neurodegradation. Its lead product candidate is ATH-1017, a blood brain barrier-penetrating, small hepatocyte growth factor/MET activator that is in various clinical trials for the treatment of Alzheimer's and Parkinson's diseases. The company also develops product candidates, which are in preclinical stage, including ATH-1019 for depression; and ATH-1018 for peripheral neuropathy. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is based in Seattle, Washington.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site